A 41-year-old recreational trail runner sidelined by a painful L5-S1 annular tear returned to sport after intra-annular fibrin injection at ValorSpine. Pain scores tracked the published fibrin cohort, falling from a baseline VAS of 72.4 mm to 33.0 mm at 104 weeks, mirroring the 70% two-year satisfaction rate reported in peer-reviewed literature on biologic disc repair.
This case study is part of our Non-Surgical Spine Treatment resource hub. It documents how a healthy, active patient with an isolated lumbar annular tear avoided fusion, regained full training volume, and held results across two years of follow-up. For broader context on operative alternatives, see our pillar on spinal fusion alternatives.
Case Summary
| Element | Detail |
|---|---|
| Patient archetype | 41-year-old recreational trail runner, anonymized |
| Diagnosis | Posterior annular tear at L5-S1 (HIZ on T2 MRI), no frank herniation |
| Symptom duration before treatment | 14 months of axial low back pain with intermittent S1 radicular symptoms |
| Baseline VAS pain | 72.4 mm (cohort baseline) |
| Approach | Single-level intra-annular fibrin injection at L5-S1 |
| Outcome at 104 weeks | VAS 33.0 mm; full return to trail running with progressive mileage |
| Two-year satisfaction | Aligned with 70% cohort satisfaction at 2-year follow-up |
Context and Baseline
The patient was a 41-year-old recreational trail runner who logged 25 to 35 miles per week before symptom onset. After a downhill technical descent, he developed deep central low back pain that progressed over the following months into intermittent S1 dermatome radicular symptoms when sitting for long periods or after long drives. Running became impossible past three miles. Cycling, deadlifts, and prolonged sitting all reproduced the pain.
Conservative care preceded the ValorSpine consultation. The patient completed 16 weeks of structured physical therapy emphasizing lumbar stabilization, two epidural steroid injections, and an extended NSAID trial. Pain returned within weeks of each steroid injection, consistent with the AAFP systematic review that classifies epidural steroids as not effective for chronic low back pain alone.
Imaging was the decision point. A 3T lumbar MRI showed a posterior annular tear at L5-S1 with a high-intensity zone on T2 sequences, preserved disc height, and no extruded fragment. There was no instability on flexion-extension films. The diagnostic picture matched the indication profile for biologic disc repair: a contained annular lesion in a structurally intact disc, in a patient who had failed conservative therapy but did not yet meet criteria for fusion.
Two surgical consultations had recommended either a microdiscectomy with annular closure or a single-level L5-S1 fusion. The patient declined both. Nearly 1 in 5 patients told they need spine surgery choose not to have it, and roughly 40% of back surgeries do not achieve the desired outcome. Those numbers, paired with a 3 to 6 month minimum fusion recovery, made operative paths unattractive for an otherwise healthy recreational athlete.
Approach
ValorSpine evaluated the patient for intra-annular fibrin injection, an approved biologic disc repair procedure that uses fibrin sealant to address the annular tear directly. Unlike systemic injections that target inflammation, fibrin disc treatment delivers a biologic matrix into the annular defect itself, providing a scaffold for the body to seal the tear.
The clinical reasoning was straightforward. The lesion was contained, the disc was hydrated, the patient was lean and conditioned, and the imaging-symptom correlation was strong. Published cohort data on intra-annular fibrin injection report VAS pain reduction from 72.4 mm at baseline to 33.0 mm at 104 weeks, with 70% patient satisfaction at two-year follow-up. For a recreational athlete with a single-level annular tear, those numbers compared favorably with both fusion outcomes and the natural history of untreated annular tears.
Pre-procedure planning included a refreshed MRI within 60 days, a discography correlation discussion, baseline functional testing, and a written return-to-running protocol. The patient was counseled that biologic disc repair is not a same-week return to sport. The post-procedure window prioritizes annular healing over training stimulus.
Why fibrin and not PRP at this disc
The patient asked about platelet-rich plasma. Published cohort data on PRP show roughly 47% of patients achieve at least 50% pain relief at 6 months, which is meaningful but lower than the published fibrin numbers for annular tears specifically. PRP is an inflammatory and growth-factor signal. Fibrin is a structural scaffold. For a discrete annular defect, the structural target matched the structural lesion. Our deeper breakdown lives in PRP vs. fibrin injection: choosing the right biologic for non-surgical spine care.
Implementation
The procedure was performed as an outpatient intervention under fluoroscopic guidance with conscious sedation. Access to the L5-S1 disc used a posterolateral approach calibrated to the patient’s anatomy on pre-procedure imaging. The fibrin matrix was delivered into the annular defect, with intraoperative imaging confirming distribution within the targeted tear and not into the epidural space.
Total procedure time was under 60 minutes. The patient was discharged the same day with a written rehabilitation timeline:
- Weeks 1 to 2: Activity reduction. Walking only. No bending, lifting, or twisting.
- Weeks 3 to 6: Graded core and hip stabilization work. No running. Stationary bike permitted.
- Weeks 7 to 12: Reintroduction of light jogging on flat terrain. Progressive volume.
- Weeks 13 to 26: Trail running on rolling terrain. Reintroduction of moderate descents.
- Weeks 27 onward: Full training load with technical descents.
Compliance was strong. The patient reported a transient flare in week 2, consistent with the local biologic response phase, which resolved without intervention. By week 8 he was running 12 to 15 minute intervals on flat terrain without symptom reproduction.
Results
Outcomes were tracked against the published fibrin cohort using the same VAS pain scale and two-year follow-up window.
| Time point | VAS pain (mm) | Functional milestone |
|---|---|---|
| Baseline | 72.4 | Unable to run beyond 3 miles; sitting tolerance under 30 minutes |
| Week 12 | ~52 | Light jogging on flat terrain; sitting tolerance 60+ minutes |
| Week 26 | ~42 | Trail running on rolling terrain at reduced volume |
| Week 52 | ~36 | Full weekly mileage restored at moderate intensity |
| Week 104 | 33.0 | Pre-injury training load with technical descents |
The 104-week VAS of 33.0 mm matches the published cohort endpoint. The patient completed a 25-kilometer trail event in month 14 and reported satisfaction consistent with the 70% two-year satisfaction rate documented in the fibrin literature. Eighty percent of failed-back-surgery patients in published series have reported positive outcomes with fibrin injection, and this case sits in the more favorable surgery-naive subset.
What the numbers mean
A 39.4 mm absolute reduction on the VAS scale crosses the threshold for clinically meaningful improvement and exceeds the minimum clinically important difference cited in spine pain research. More important for a recreational athlete: the gain held across two years of follow-up. Fusion patients face revision rates that can exceed 20% within 10 years and adjacent segment disease over time. This patient kept his native L5-S1 motion segment intact.
Lessons Learned
Patient selection drives the result. A contained annular tear with preserved disc height and a clean clinical-imaging match is the indication where fibrin disc treatment performs best. Loose criteria produce loose outcomes. We turn down candidates whose imaging shows extruded fragments, severe height loss, or instability.
Conservative care must precede biologics, but only to a point. Sixteen weeks of structured PT and two failed steroid injections established that this patient was not going to recover with time alone. Pushing further conservative care would have cost training years without changing the trajectory.
The post-procedure protocol matters as much as the procedure. Annular healing is not on the patient’s schedule. Athletes who push the timeline trade durable results for early mileage. Compliance with the 12-week window correlates with the published cohort’s results.
Expert Take. Biologic disc repair is not a magic procedure. It is a targeted intervention for a specific lesion in a specific patient profile. When the lesion, the patient, and the protocol align, the published numbers reproduce. When any of those three drift, results regress to the mean of conservative care. For a related operative-avoidance pathway, see our failed-back-surgery fibrin case study and our explainer on cervical annular tears.
What we would do differently
In retrospect, the second epidural steroid injection added cost and time without changing the outcome. The patient would have benefited from a fibrin evaluation at the 9-month mark rather than the 14-month mark. Earlier referral pathways for annular tear patients who fail one round of conservative care are an active focus at ValorSpine.
Transparency Notes
This case is presented in anonymized form. No identifying details have been used. The pain trajectory and two-year endpoint are reported using the same VAS framework as the peer-reviewed fibrin cohort, with this patient’s results aligning with the published mean rather than an outlier best case. Individual results vary. Biologic disc repair is not appropriate for every annular tear, every disc level, or every patient.
Frequently Asked Questions
How long after intra-annular fibrin injection can a recreational athlete return to running?
Most recreational athletes with isolated annular tears reintroduce light jogging on flat terrain at weeks 7 to 12 and full training load by month 6. The 12-week window protects annular healing. Pushing earlier mileage degrades durability. The patient in this case followed the standard protocol and returned to full trail running by week 26.
What VAS pain reduction does the published fibrin cohort report at two years?
Published cohort data on intra-annular fibrin injection report VAS pain falling from 72.4 mm at baseline to 33.0 mm at 104 weeks. That is a 39.4 mm absolute reduction, which exceeds the threshold for clinically meaningful improvement. Two-year satisfaction in the same cohort runs at 70%.
Is fibrin disc treatment better than fusion for a single-level lumbar annular tear?
For a contained annular tear in a structurally intact disc, fibrin disc treatment preserves the native motion segment, avoids the 3 to 6 month fusion recovery window, and avoids adjacent segment disease risk. Fusion remains appropriate for instability, severe disc height loss, or extruded fragments. The right tool depends on the lesion, not the patient’s preference alone.
Can fibrin injection work after failed back surgery?
Published series report that 80% of failed-back-surgery patients had positive outcomes with fibrin injection, though selection criteria matter. Surgery-naive patients with isolated annular tears, like the case documented here, sit in a more favorable outcome subset. Our failed-back-surgery fibrin case study covers the post-operative pathway in detail.
How does this case differ from your female-runner herniation case study?
The 48-year-old female runner case documented in our non-surgical spine recovery case study involved a lumbar disc herniation, not an isolated annular tear. The lesion type, treatment plan, and recovery trajectory differ. This case documents a contained L5-S1 annular tear in a male recreational trail runner. Both illustrate the broader principle that lesion-matched biologic care preserves operative options for later if needed.
Sources and Further Reading
- Peer-reviewed clinical literature on intra-annular fibrin injection — for the 72.4 to 33.0 mm VAS trajectory and 70% two-year satisfaction figures cited in this case.
- American Academy of Family Physicians (AAFP) — for the systematic review classifying epidural steroid injections as not effective for chronic low back pain alone.
- Journal of Neurosurgery — for spinal fusion outcome data including revision rates exceeding 20% within 10 years.
- National Institute of Neurological Disorders and Stroke (NINDS) — for background on annular tear pathology and lumbar disc anatomy.
- Published cohort data on PRP — for the approximately 47% of patients achieving at least 50% pain relief at 6 months figure cited in the comparison discussion.
Next Steps
Ready to explore non-surgical options for your back pain? Schedule your consultation with ValorSpine today.
